Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 10
Submit an article Journal homepage
2,395
Views
19
CrossRef citations to date
0
Altmetric
Case Report

Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient

Masoud Etemadifara Department of Neurosurgery, Isfahan University of Medical Sciences, Isfahan, Iran
,
Amirhossein Akhavan Sigarib Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
,
Nahad Sedaghatb Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran;c Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran
,
Mehri Salarid Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
&
Hosein Nourib Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran;c Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, IranCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1808-0443
ORCID Icon
Pages 3481-3483 | Received 11 Mar 2021, Accepted 05 May 2021, Published online: 20 May 2021

References

  • Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, Wrammert J, Nyhoff L, Davis CW, Adekunle O. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3):100040. doi:10.1016/j.xcrm.2020.100040.
  • Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, … Bijker E. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020;397:99–111.
  • Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–81. doi:10.1016/S0140-6736(21)00234-8.
  • Kremer EJ. Pros and cons of adenovirus-based SARS-CoV-2 vaccines. Mol Ther. 2020;28(11):2303–04. doi:10.1016/j.ymthe.2020.10.002.
  • Stephenson KE, Le Gars M, Sadoff J, De Groot AM, Heerwegh D, Truyers C, Barouch DH, Loos C, Chandrashekar A, McMahan K. Immunogenicity of the Ad26. COV2. S vaccine for COVID-19. JAMA. 2021;325(15):1535. doi:10.1001/jama.2021.3645.
  • Baker D, Roberts CA, Pryce G, Kang AS, Marta M, Reyes S, Amor S, Giovannoni G, Amor S. COVID‐19 vaccine‐readiness for anti‐CD20‐depleting therapy in autoimmune diseases. Clin Exp Immunol. 2020;202(2):149–61. doi:10.1111/cei.13495.
  • Maillart E, Papeix C, Lubetzki C, Roux T, Pourcher V, Louapre C. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? Mult Scler Relat Disord. 2020;46:102482. doi:10.1016/j.msard.2020.102482.
  • Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2021;1–25. doi:10.1007/s00415-020-10362-z.
  • Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung HP, Magyari M, Oreja-Guevara C, Trojano M, Wiendl H, Filippi M. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol. 2021;1–8. doi:10.1007/s00415-021-10545-2.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.